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Abstract
To increase the potency of DNA vaccines, we constructed genetic fusion vaccines encoding antigen, secretion signal, and/or chemokine
RANTES. The DNA vaccines encoding secreted hepatitis B surface antigen (HBsAg) were constructed by inserting HBsAg gene into an
expression vector with an endoplasmic reticulum (ER)-targeting secretory signal sequence. The plasmid encoding secretory HBsAg
(pER/HBs) was fused to cDNA of RANTES, generating pER/HBs/R. For comparison, HBsAg genes were cloned into pVAX1 vector with
no signal sequence (pHBs), and further linked to the N-terminus of RANTES (pHBs/R). Immunofluorescence study showed the cytoplasmic
localization of HBsAg protein expressed from pHBs and pHBs/R, but not from pER/HBs and pER/HBs/R at 48 h after transfection. In mice,
RANTES-fused DNA vaccines more effectively elicited the levels of HBsAg-specific IgG antibodies than pHBs. All the DNA vaccines
induced higher levels of IgG2a rather than IgG1 antibodies. Of RANTES-fused vaccines, pER/HBs/R encoding the secreted fusion protein
revealed much higher humoral and CD8 T cell-stimulating responses compared to pHBs/R. These results suggest that the immunogenicity
of DNA vaccines could be enhanced by genetic fusion to a secretory signal peptide sequence and RANTES.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Despite significant progress made, the immunogenicity
of DNA vaccines still must be improved. One of the factors
contributing to the low efficacy of intramuscularly admin-
istered DNA vaccines could be the expression of DNA
vaccines in the muscle cells lacking immune costimulatory
molecules such as B7 (McKenzie et al., 2001). Moreover,
the cytoplasmic localization of the expressed antigen pro-
teins in the muscle cells could limit the exposure of antigens
to the professional immune cells (Boyle et al., 1997). To
overcome such problems, it might be desirable to develop
new genetic immunization systems that can allow the cel-
lular secretion of the antigen proteins after expression and
the targeting of the secreted proteins to the immune cells.
The fusion of immune cell-recruiting agent to an antigen
might be one way to deliver the antigen to the immune
system. Boyle et al. (1998) reported the enhanced immune
responses to a DNA vaccine encoding a fusion antigen that
was directed to the sites of immune induction. Recently,
immune cell-recruiting chemokines have been studied as
molecular adjuvants of DNA vaccines (Eo et al., 2001;
Nomura et al., 2001). A previous study demonstrated that
genetic fusion of chemokines to a self-tumor antigen could
induce protective and T cell-dependent antitumor immunity
(Biragyn et al., 1999). Though most of chemokine-fused
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DNA vaccines have focused on the treatment of tumors, a
recent report demonstrated the new application of chemo-
kine-fused DNA vaccines for prevention of viral infection
(Biragyn et al., 2002). In the study, they reported that the
DNA vaccines encoding human immunodeficienty virus-1
glycoprotein 120 fused with monocyte chemoattractant pro-
tein-3 or macrophage-derived chemokine could increase the
titers of virus-neutralizing activity. However, there is lack
of understanding of the effect of endoplasmic reticulum-
targeting secretory signal on the immunogenicity of chemo-
kine-fused DNA vaccines.
In this study, we tested whether the humoral and cellular
immunogenicity of DNA vaccines could be improved by
fusion with a chemokine and, if so, whether the immuno-
genicity could be further affected by the cellular fate after
expression. As a chemokine, RANTES (regulated on acti-
vation normal T cell expressed and secreted) has been used
in this study. The major receptors of RANTES, CCR1 and
CCR5, have been reported to mediate endocytosis (Solari et
al., 1997; Mueller et al., 2002), which might be important
for intracellular delivery and processing of secreted chemo-
kine-fused antigen. Using hepatitis B surface antigen (HBsAg)
as a model antigen, we report here the enhanced humoral
immune responses and CD8 T cell-stimulating effects of
HBsAg DNA vaccine encoding an endoplasmic reticulum
(ER)-targeting secretion signal peptide sequence and RAN-
TES.
Results
Effect of an ER-targeting signal peptide on the cellular
fates of HBsAg
Various HBsAg DNA vaccines were constructed by sim-
ple insertion of gene fragments or by insertion of digested
polymerase chain reaction (PCR) products after amplifica-
tion with primers having desired restriction sites (Fig. 1).
Table 1 shows the sequences of oligonucleotide primers
used for construction of genetic vaccines. pHBs encoding
HBsAg lacks ER-targeting secretion signal (Fig. 1a). In
contrast, pER/HBs was constructed to design a DNA vac-
cine encoding secreted HBsAg (Fig. 1d). Two types of
HBsAg/RANTES fusion vaccines, p/HBs/R (Fig. 1c) and
pER/HBs/R (Fig. 1e), were constructed to encode nonsecre-
tory and secretory form of fusion proteins, respectively.
To test whether the HBsAg genetic fusion constructs
could express HBsAg in the cell levels, and if so, whether
the mRNA expression levels differ among the various DNA
constructs, the expression levels of HBsAg were measured
at 6 h after transfection. The presence of mRNA transcripts
of HBsAg was observed in all the DNA constructs except
the group treated with pR (Fig. 1b) lacking HBsAg moiety
(Fig. 2a). Moreover, semiquantitative reverse transcription
(RT)-PCR results show that there were no significant dif-
ferences in the expression levels of HBsAg among the
constructs at 6 h after transfection (Fig. 2b).
Though there was no difference in the expression levels
of HBsAg at an early time point after transfection, the
presence of an ER-targeting signal peptide sequence in the
expression vector affected the trafficking of expressed pro-
teins in the cells. The immunofluorescence study measured
at 48 h after transfection showed that the cellular fates of
expressed proteins contrasted between the DNA vaccines
after transient transfection. The cells transfected with pHBs
or pHBs/R showed the immunofluorescence of HBsAg pro-
teins in the cytoplasm (Fig. 3a and b), whereas the cells
transfected with pER/HBs or pER/HBs/R displayed little
cellular immunofluorescence (Fig. 3c and d). Expression of
RANTES was observed in the cells transfected with pR and
with DNA fusion vaccines encoding RANTES moieties
such as pHBs/R and pER/HBs/R (Fig. 4a). However, the
secretion of RANTES into cell culture supernatant was
shown in the group transfected with pR or pER/HBs/R
(Fig. 4b).
To estimate the in vivo chemotactic ability of RANTES
derived from DNA constructs such as pR and pER/HBs/R,
the expression of chemokine receptor CCR5 was measured
following the intramuscular injection of various plasmid
DNA. The muscle tissues from the untreated mice showed
Fig. 1. Construction scheme of HBsAg DNA vaccines. (a) pHBs was
generated by cloning HBsAg gene fragment into the XhoI site of pVAX1
vector. (b) The cDNA fragment of RANTES was inserted into EcoRI/NotI
sites of pVAX1 vector. (c) HBsAg gene was amplified using primers A and
B, digested with HindIII and EcoRI respectively, and inserted into the
HindIII/EcoRI sites of pVAX1. The polymerase chain reaction products of
RANTES, amplified using primers C and D, were cut with EcoRI and NotI,
respectively, and inserted into the EcoRI/NotI sites in pVAX1. (d) HBsAg
gene fragment was inserted into the NotI site pCMV/myc/ER. (e) HBsAg
gene was amplified by using primers E and F, digested with XhoI and NotI,
respectively, and inserted into the XhoI/NotI sites of pVAX1 vector. The
cDNA fragment of RANTES was then amplified using primers G and D,
digested with NotI, and inserted into the NotI site of pCMV/myc/ER.
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lack of CCR5 expression. pVAX1 expression vector alone
induced slight expression of CCR5. In contrast, both pR and
pER/HBs/R revealed higher expression of CCR5 in the
muscle tissues than did pVAX1 vector (Fig. 5).
Humoral immune responses to genetic fusion vaccines
encoding HBsAg and RANTES
The induction of HBsAg-specific antibodies was affected
by the genetic fusion of HBsAg with RANTES and by the
cellular fate of expressed proteins. Fig. 6a shows that the
serum levels of IgG antibodies were significantly higher in
the mice immunized with pER/HBs/R than with pER/HBs,
Table 1
The sequences of oligonucleotide primers used to construct expression
plasmids
Primer Sequence (5–3) Sense or
antisense
A ACCCAAGCTTGGTACCGGGCC Sense
HindIII (start codon located at 37 bp
downstream)
B TTAGGAATTCAATGTATACCCA Antisense
EcoRI (stop codon change, TTA 3 TTC)
C CATGAATTCCCCACAGCGTTTGC Sense
EcoRI (start codon located at 20 bp
downstream)
D CAACGCGGCCGCAGCTGACATAC Antisense
NotI (stop codon located at 132 bp downstream)
E CCCCTCGAGGATTGGGGACCCTG Sense
XhoI (start codon located at 22 bp downstream)
F GTTGCGGCCGCAATGTATACCCAAAGAC Antisense
NotI (stop codon change, TTA 3 CGC)
G CCCACAGCGGCCGCCGCGGGTAC Sense
NotI (start codon located at 15 bp downstream)
Fig. 2. mRNA expression levels of HBsAg in C2C12 cells. (a) C2C12 cells
were transfected with various DNA constructs. At 6 h after transfection, the
mRNA expression of HBsAg in the cell pellets was measured by reverse
transcription–polymerase chain reaction. The cDNA samples were ampli-
fied by using specific primers of HBsAg and GAPDH. (b) The density
ratios of HBsAg/GAPDH were determined for each DNA construct. The
ratio of HBsAg/GAPDH was obtained by dividing the cDNA band density
of HBsAg with that of the corresponding GAPDH.
Fig. 3. Immunofluorescence of HBsAg protein in C2C12 cells. C2C12
cells, grown on coverslips, were transfected with pHBs (a), pHBs/R (b),
pER/HBs (c), or pER/HBs/R (d) for 2 h. At 48 h after transfection, the cells
were fixed, permeabilized, and incubated with anti-HBsAg antibody. The
cells were then incubated with fluorescein-conjugated secondary antibody
and observed under a fluorescence microscope. The experiment was re-
peated three times with similar results. Scale bar: 10 m.
Fig. 4. Western blot of RANTES in C2C12 cells. C2C12 cells were
transfected with each plasmid DNA using Lipofectamine. At 24 h after
transfection, the cell pellets (a) and supernatants (b) were collected. The
presence of RANTES proteins in each fraction was tested by Western blot
using a goat anti-RANTES antibody and horseradish peroxidase-conju-
gated anti-goat IgG antibody. The experiment was repeated three times
with similar results.
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indicating the adjuvant effect of genetically fused RANTES.
Moreover, the higher levels of IgG were observed in pER/
HBs encoding secretory HBsAg compared with pHBs lack-
ing the ER-targeting secretory signal peptide sequence. Of
RANTES-fusion vaccines, the induction of IgG responses
was higher in pER/HBs/R compared to pHBs/R (Fig. 6b).
Moreover, the DNA vaccines expressing the secreted HB-
sAg protein fused to RANTES differed from the physical
mixture of DNA vaccine encoding secreted HBsAg and the
plasmid encoding RANTES. The coadministration of pER/
HBs and pR revealed IgG levels lower than did pER/HBs/R
(Fig. 6b).
All the genetic vaccines tested in this study induced the
higher levels of IgG2a than IgG1 antibodies. The HBsAg
genetic vaccine with an ER-targeting secretion signal se-
quence, pER/HBs, produced the higher levels of IgG2a and
IgG1 relative to the DNA vaccine encoding cytoplasmic
HBsAg, pHBs (Fig. 7). Among DNA vaccines tested, pER/
HBs/R showed the highest IgG1 and IgG2a levels (Fig. 7).
CD8 T cell-stimulating effects of HBsAg genetic fusion
vaccines
Similar to the humoral immune responses, the CD8 T
cell-stimulating effects of HBsAg DNA vaccines were in-
creased by genetic fusion to RANTES and by introduction
of a secretor signal sequence. The DNA vaccines expressing
HBsAg fused to RANTES (pHBs/R and pER/HBs/R) dis-
played the significantly higher CD8 T cell-stimulating
activity relative to pHBs encoding HBsAg alone (Fig. 8).
The DNA vaccines expressing the secretory HBsAg
showed the higher CD8 T cell-stimulating effects than did
other vaccines encoding cytoplasmic HBsAg. Between the
DNA vaccines encoding HBsAg alone, pER/HBs showed
the higher CD8 T cell-stimulating activity than did pHBs.
Of RANTES-fusion vaccines, pER/HBs/R encoding se-
creted form of HBsAg/RANTES fusion protein showed the
higher CD8 T cell-stimulating activity in comparison with
pHBs/R encoding cytoplasmic form of HBsAg/RANTES
fusion protein. The administration of pHBs/R and the co-
administration of pER/HBs and pR did not significantly
differ in the cellular immune responses. However, the co-
administration of pER/HBs and pR displayed significantly
lower effects relative to pER/HBs/R.
Discussion
In this study, we demonstrated that the genetic fusion
with chemokine RANTES could enhance the immunogenic-
ity of HBsAg DNA vaccines. Moreover, our results indicate
the importance of cellular fate in the immunogenicity of
genetic fusion vaccines.
The immunofluorescence data indicate that the cellular
fates of DNA vaccines could be altered by the presence of
an ER-targeting secretion signal peptide sequence. We ob-
Fig. 6. IgG antibody responses of DNA vaccines. Mice were immunized by
intramuscular injection of 100 g of each plasmid DNA vaccine at 0, 4,
and 8 weeks. At various time points after the first immunization, the blood
was collected from the tail vein, and the serum levels of anti-HBsAg IgG
antibodies were determined by enzyme-linked immunosorbent assay. The
results are expressed as mean  SE values (n  5).
Fig. 5. mRNA expression of CCR5 in muscle tissues. (a) Mice were
intramuscularly injected with various DNA constructs. As a control, un-
treated mice were used. At 48 h after administration, the mRNA expression
of CCR5 in the muscle tissues was measured by reverse transcription–
polymerase chain reaction. The cDNA samples were amplified by using
specific primers of CCR5 (a) and GAPDH (b). The result is the represen-
tative figures of three separate experiments.
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served the lack of immunofluorescence observed at 48-h
transfection with pER/HBs or pER/HBs/R (Fig. 3). Given
the similar mRNA expression levels of HBsAg derived
from various DNA constructs in the cell pellets at 6 h after
transfection (Fig. 2), it is unlikely that pER/HBs and pER/
HBs/R could be less efficiently transcribed to HBsAg than
pHBs. Rather, the lack of immunofluorescence appears to
be due to the secretion of expressed HBsAg/RANTES fu-
sion proteins to the extracellular environments, supporting
the strength of the artificial ER-targeting signal sequence in
modulating the cellular fate of HBsAg and RANTES fusion
proteins.
In our Western blot study (Fig. 4), pHBs/R did not
secrete RANTES into supernatant at the time point tested.
pHBs/R was constructed to encode RANTES containing its
endogenous secretory signal sequence following the gene of
HBsAg. It appears that the fusion of RANTES secretory
signal to the N-terminal of HBsAg might have resulted in
the protein systhesis in cytosolic free ribosomes, rather than
ER-bound ribosomes leading to the secretion of expressed
proteins. Currently, it remains unclear by which mecha-
nisms pHBs/R construct with a secretory signal in the mid-
dle of the antigen and RANTES sequence resulted in the
cytosolic protein synthesis. However, the possibility exists
that the binding of a secretory signal sequence with a signal
receptor might not be optimal in the HBsAg/RANTES chi-
meric fusion gene structure.
Expression of CCR5 has been studied as one of the ways
to measure the biological effects of RANTES. CCR5, one of
RANTES receptors, has been known to be highly expressed
on monocytes and dendritic cells showing chemotaxis to
RANTES. The cells showing the high grade chemotaxis to
RANTES were shown to express the higher levels of CCR5
receptors (Cockwell et al., 2002). If monocytes and den-
dritic cells migrated in response to RANTES expressed
from the DNA constructs, the induced migration of those
immune cells may increase the levels of CCR5 in the in-
jection sites. Indeed, to characterize the biological function
of synthetic RANTES, Vita et al. (2002) showed that bio-
tinylated RANTES could modulate the expression of CCR5
expression in the same manner as unmodified RANTES.
Based on these findings, our observation that both pR and
pER/HBs/R showed the higher expression levels of CCR5
than did pVAX1 vector at the injection site (Fig. 5) may
suggest that HBs/R fusion protein expressed from pER/
HBs/R could retain the chemotactic ability of RANTES.
The humoral immunogenicity of HBsAg DNA vaccines
was enhanced by genetic fusion with RANTES. The stron-
ger IgG levels of pER/HBs/R in comparison with pER/HBs
imply that the genetic fusion of HBsAg to RANTES might
be more effective in inducing humoral immune responses
compared to HBsAg alone. Previously, the increased hu-
moral antibody responses were observed after treatment
with RANTES (Lillard et al., 2001). The report suggested
that RANTES might enhance the humoral antibody re-
sponses through the induction of cytokine and costimulatory
molecules and through the expression of cytokine receptors
on T lymphocytes.
In addition to genetic fusion with RANTES chemokine
genes, the cellular fate appears to be a role as an important
factor affecting the immunogenicity of genetic vaccines.
Although both pHBs/R and pER/HBs/R encode RANTES-
fused HBsAg, the higher humoral responses of pER/HBs/R
over pHBs/R indicate that the presence of an ER-targeting
secretion signal sequence might be required for higher po-
tency of DNA fusion vaccines. Similarly, the higher im-
Fig. 7. IgG1 and IgG2a subtype antibody responses of DNA vaccines. Mice
were immunized by intramuscular injection of 100 g of each plasmid
DNA vaccine at 0, 4, and 8 weeks. At various time points after the first
immunization, the blood was collected from the tail vein, and the serum
levels of anti-HBsAg IgG1 and IgG2a subtype antibodies were determined
by enzyme-linked immunosorbent assay. The results are expressed as mean
 SE values (n  5).
Fig. 8. HBsAg-specific CD8 T-cell stimulation of DNA vaccines. Mice
were immunized by intramuscular injection of 100 g of each plasmid
DNA vaccines at 0, 4, and 8 weeks. At 12 weeks after immunization of
mice with various DNA vaccines, mice were killed and CD8 T cells were
isolated. Responses are shown as the number of HBsAg-specific interfer-
on- spot-forming cells (SFC)/106 CD8 T cells. The results are expressed
as mean  SE values (n  5).
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mune response of pER/HBs encoding secreted HBsAg in
comparison with pHBs indicates the importance of cellular
localization in the potency of DNA vaccines. Consistent
with our observation, Boyle et al. (1997) reported that
cytotoxic T lymphocyte and antibody responses were sub-
optimal when the cellular location of antigen was cytoplas-
mic after intramuscular DNA immunization. Improvement
of humoral and cellular immune responses was reported
when the plasmid DNA encoding the outer surface protein
C of Borrelia burgdorferi was fused to the native ER-
targeting secretory signal sequences of tissue plasminogen
activator (Weiss et al., 2000).
The highest IgG induction was observed in the groups
immunized with pER/HBs/R. RANTES has been reported
to be endocytosed via receptors on dendritic cells and
monocytes (Solari et al., 1997). It is speculated that the
secreted form of HBsAg and RANTES fusion proteins
might be taken up by antigen-presenting cells through che-
mokine receptors such as CCR1 and CCR5. Moreover,
given the chemokine cascade-inducing activity of RANTES
in dendritic cells (Fischer et al., 2001), we cannot exclude
the possibility that RANTES-mediated chemokine ampli-
fication in dendritic cells may also shape the microenvi-
ronment, potentially enhancing the immune responses to
RANTES-fused HBsAg.
We measured antigen-specific CD8 T-cell stimulation
to test the cell-mediated immunogenicity of various DNA
vaccines. Antigen-specific CD8 T cells are known to be a
major host defense against viral infection (Yewdell and Hill,
2002). CD8 T cells are responsible for the antigen-specific
recognition and elimination of virus-infected cells through
direct killing and production of antiviral cytokines (Appay
and Rowland-Jones, 2002). Several studies have employed
antigen-specific CD8 T-cell responses to test the cell-
mediated immunogenicity of DNA vaccines. CD8 T-cell
responses were measured following coimmunization with
plasmids expressing different antigens of murine cytomeg-
alovirus (Ye et al., 2002). Antigen-specific CD8 T-cell
responses were studied after immunization of rhesus ma-
caques with human immunodeficiency virus gag DNA vac-
cines (Caulfield et al., 2002). Given the importance of an-
tigen-specific CD8 T cells in cell-mediated immunity, we
determined the stimulation of HBsAg-specific CD8 T cells
using ELISPOT assay.
The genetic fusion with RANTES chemokine also in-
creased the antigen-specific CD8 T cell-stimulating effects
of HBsAg DNA vaccines. The higher number of HBsAg-
specific CD8 T cells in pER/HBs/R over pER/HBs sup-
ports the adjuvant role of RANTES in the induction of
cellular immune responses. Previously, the induction of cell-
mediated antitumor immunity was reported for lymphoma-
specific single chain antigen genetically fused to chemo-
kines such as monocyte chemotactic protein-3 or interferon
inducible protein-10 (Biragyn et al., 1999). DNA vaccines
encoding RANTES were also shown to enhance CD4 T
cell-mediated protective immunity against herpes simplex
virus type 2 (Sin et al., 2000).
In conclusion, our results suggest that the genetic fusion
of secreted antigens to RANTES might be a useful approach
to enhance the immunogenicity of DNA vaccines.
Materials and methods
Construction of genetic fusion vaccines
The HBsAg-encoding sequence, subtype ayw, was ob-
tained from the plasmid pRc/CMV-HBs(S) (a kind gift of
Aldevron, Fargo, ND, USA). The coding sequence of HB-
sAg was inserted into the XhoI site of the pVAX1 expres-
sion vector (Invitrogen, CA, USA) generating the plasmid
pHBs (Fig. 1a). The eukaryotic expression vector pVAX1
contains the cytomegalovirus early promoter/enhancer se-
quence and kanamycin resistance gene. Murine RANTES
cDNA was kindly provided by Dr. T. Yoshimura (National
Cancer Institute, MD, USA). For expression plasmid of
RANTES, the cDNA fragment including the native 23-
amino acid leader sequence (279-bp) was inserted into
EcoRI/NotI sites of pVAX1 vector, resulting in pR (Fig.
1b). To construct pHBs/R, HBs gene was amplified from
pHBs using primers A and B, digested with HindIII and
EcoRI, respectively, and inserted into the multicloning sites
of pVAX1 vector. Then, RANTES cDNA, amplified from
pBluescript/RANTES using primers C and D, was cut with
EcoRI and NotI and inserted into the EcoRI and NotI sites
of pVAX1 vector (Fig. 1c).
To induce the secretion of expressed HBsAg protein
from the cells, HBsAg gene was inserted into the multiclon-
ing sites of pCMV/myc/ER (Invitrogen, CA, USA) with the
cytomegalovirus early promoter/enhancer sequence and an
ER-targeting signal sequence in the backbone (Fig. 1d). For
pER/HBs, HBsAg-encoding gene fragment was cut from
pHBs using NotI, then inserted into the NotI site of pCMV/
myc/ER vector. For genetic fusion of RANTES to HBsAg
(Fig. 1e), HBsAg-encoding fragment was amplified from
pHBs using primers E and F, cut with XhoI and NotI, then
inserted into XhoI and NotI sites of the secretion signal
pCMV/myc/ER vector. Then, RANTES cDNA was ampli-
fied using primers G and D, digested with NotI, and inserted
into the NotI site of pCMV/myc/ER vector, generating pER/
HBs/R. All the plasmid DNAs in this study were amplified
using Escherichia coli Top10F and purified using Qiagen
Giga Prep Kit (Qiagen, CA, USA).
Semiquantitative analysis of HBsAg expression levels in
C2C12 cells
To determine the mRNA expression levels of HBsAg
genes, semiquantitative RT-PCR was performed. C2C12
mouse muscle cells (kindly provided from Dr. YI Yeom,
Korea Research Institute of Bioscience and Biotechnology,
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Korea) were grown on a 12-mm coverslip at a density of 1
 105 cells and transfected with pHBs, pR, pHBs/R, pER/
HBs, or pER/HBs/R using Lipofectamine (GibcoBRL, MA,
USA) for 2 h. After 6-h incubation, total cellular RNA was
extracted from the cells using TRIzol reagent (GibcoBRL).
One microgram of total RNA was reverse transcribed, and
amplified by PCR using primers as described previously
(Lai et al., 1996). The murine housekeeping gene of glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as an endogenous reference. The same amount of cDNA
was amplified by PCR for GAPDH using the primers as
described previously (Oh et al., 2001). The PCR products
were electrophoresed on a 2% agarose gel, and visualized
with ethidium bromide. The density of each band was mea-
sured using a gel-doc image analyzer (Vilber Lourmat,
France). The band intensities of HBsAg were normalized
with those of corresponding GAPDH.
Immunofluorescence
The cellular fate of HBsAg was tested by immunofluo-
rescence. C2C12 mouse muscle cells were grown on a
12-mm coverslip at a density of 1  105 cells and trans-
fected with pHBs, pR, pHBs/R, pER/HBs, or pER/HBs/R
using Lipofectamine (GibcoBRL) for 2 h. At 48 h after
transfection, the cells were fixed at room temperature for 20
min using a modified paraformaldegyde-lysine-periodate
fixative (Oh and Swanson, 1996). Next, the cells were
washed, permeabilized for 20 s using cold methanol, and
incubated for 2 h with mouse anti-HBsAg monoclonal an-
tibody (1:250, Aldevron, USA). The cells were then washed
and incubated for 1 h with fluorescein-conjugated goat anti-
mouse IgG antibody (1:250, Pierce, IL, USA). Finally, the
cells were washed and mounted in a phostostabilizer (90%
glycerol, 10% phosphate buffer, 1 mg/ml phenylenedi-
amine), and observed under a fluorescence microscope (Ni-
kon H-III, Japan).
Western blot analysis
The expression of RANTES in the series of DNA vac-
cine constructs was tested by using Western blot. C2C12
cells (1  106 cells) were seeded onto 60-mm tissue culture
plates and cultured in RPMI 1640 media supplemented with
10% fetal bovine serum until the cells reached approxi-
mately 80% confluence. The cells were transfected with
plasmid DNA using Lipofectamine as specified by the man-
ufacturer. At 24 h after transfection, the cell pellets and
supernatants were collected and stored at 70°C until anal-
ysis. For Western blot analysis, the nitrocellulose blot mem-
branes were incubated with goat anti-murine RANTES an-
tibody (1:2000, Santacruz, CA, USA). For detection of
RANTES, horseradish peroxidase-conjugated anti-goat IgG
antibody (1:2000, Pierce) was used as the secondary anti-
body.
CCR5 expression in muscle tissues
The expression of CC chemokine receptor, CCR5, was
measured in the muscle tissues using RT-PCR. Mice were
intramuscularly administered with pVAX1, pR, or pER/
HBs/R at a dose of 100 g of plasmid DNA in 20 l of
phosphate-buffered saline. At 48 h after injection, the mus-
cle tissues near the injection sites were removed and total
RNA was extracted from the tissues using TRIzol reagent
(GibcoBRL). One microgram of total RNA was reverse
transcribed, and amplified by PCR using primers specific
for murine CCR5 receptors as described previously (Fischer
et al., 2000). The same amount of cDNA was amplified by
PCR for GAPDH as described previously (Oh et al., 2001).
Immunization of mice
For immunization, female BALB/c mice were supplied
from Seoul National University animal center (Seoul, Ko-
rea). The mice were used at 6–8 weeks of age and received
food and water ad libitum. Each mouse was given intramus-
cular injections into the left quadriceps at a dose of 100 g
of plasmid DNA in 20 l of phosphate-buffered saline. All
mice were boosted with equal doses after 4 and 8 weeks
from the first injection.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to analyze the induction of humoral
immune responses against HBsAg in the immunized mice.
Serum samples were collected by tail bleeding at different
time points after immunization and analyzed for the pres-
ence of HBsAg-specific antibodies. A 96-well plate was
coated with recombinant HBsAg proteins (2 g/ml, kindly
provided from LG Chem., South Korea). After blocking of
the plates with 2% bovine serum albumin (BSA), dilutions
of test sera (1:100) were added to each well and incubated
for 2 h at room temperature. The plates were then washed,
and the levels of bound antibodies were detected with horse-
radish peroxidase-conjugated goat anti-mouse IgG, IgG1, or
IgG2a antibodies. Color was generated by adding 1-Step
Turbo TMB-ELISA (Pierce), and absorbance at 450 nm was
measured by using an ELx-800 ELISA reader (Bio-Tek
Instruments, VT, USA).
Enzyme-linked spot (ELISPOT) assay
At 12 weeks after the first immunization of mice with
various DNA vaccines, mice were killed and the spleens
were removed. The spleen cells were then mixed with mag-
netic beads coated with anti-mouse CD8 antibody (Macs,
Germany), and CD8 T cells were isolated according to
instructions of the manufacturer. Multiscreen 96-well
plates, MAIP NOB 10 (Millipore, MA, USA), were coated
with a monoclonal antibody against human interferon-
gamma (IFN-), clone R4-6A2 (Pharmingen, CA, USA).
90 S.J. Kim et al. / Virology 314 (2003) 84–91
The following day, CD8 T cells were plated at 2  105
cells per well in 200 l of complete RPMI medium (50
U/ml penicillin and 50 g/ml streptomycin). HBsAg-spe-
cific CD8 epitope peptides (IPOSLDSWWTSL, Schirm-
beck et al., 1998) were supplied from Peptron Inc. (Daejeon,
South Korea), and added to the CD8 T-cell cultures at a
final concentration of 2 g/ml. As a positive control, con-
canavalin A (Sigma, MO, USA) was added to control wells
at a final concentration of 2 g/ml. The plates were incu-
bated at 37°C, 5% CO2, for 36 h. After washing the plates,
biotinylated anti-mouse IFN-, clone XMG1.2 (Pharmin-
gen) was added at a concentration of 2 g/ml and the plates
were incubated at room temperature for 2 h. After three
washings, streptavidin-conjugated alkaline phosphatase
(Vector, CA, USA) was added at 1:2000 dilutions. After
incubation at room temperature for 1 h, the plates were
washed, and the spots were developed with 1-Step NBT/
BCIP reagent (Pierce). The number of spot-forming cells
was counted by using an image analyzer (Vilber Lourmat,
France).
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